Trial Profile

Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bone marrow-derived allogenic mesenchymal stem cells-ImmunityBio (Primary)
Indications Adult respiratory distress syndrome; Hypoxaemia; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; Therapeutic Use
Sponsors ImmunityBio; NantKwest

05 Sep 2024 The protocol has been amended to change in study primary endpoint now the AEs will be assessed Within 30 Days of Randomization.
05 Sep 2024 Status changed from active, no longer recruiting to discontinued.
31 Jan 2022 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com